As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
This article was originally published in The Pink Sheet Daily
Executive Summary
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.